Members of the genus Acanthamoeba are facultative pathogens of humans, causing a sight-threatening keratitis and a fatal encephalitis. We have targeted myosin-IC by using small interfering RNA (siRNA) silencing as a therapeutic approach, since it is known that the function of this protein is vital for the amoeba. In this work, specific siRNAs against the Acanthamoeba myosin-IC gene were developed. Treated and control amoebae were cultured in growth and encystment media to evaluate the induced effects after myosin-IC gene knockdown, as we have anticipated that cyst formation may be impaired. The effects of myosin-IC gene silencing were inhibition of cyst formation, inhibition of completion of cytokinesis, inhibition of osmoregulation under osmotic stress conditions, and death of the amoebae. The finding that myosin-IC silencing caused incompletion of cytokinesis is in agreement with earlier suggestions that the protein plays a role in cell locomotion, which is necessary to pull daughter cells apart after mitosis in a process known as "traction-mediated cytokinesis". We conclude that myosin-IC is a very promising potential drug target for the development of much-needed antiamoebal drugs and that it should be further exploited for Acanthamoeba therapy.
A
canthamoeba is a genus of small amoebae that are ubiquitous in the human environment. They alternate between feeding moving trophozoites and, when conditions are unfavorable, a resting cyst stage. Members of this genus are facultative human pathogens that cause the serious eye infection Acanthamoeba keratitis and a rare but usually fatal infection known as granulomatous Acanthamoeba encephalitis (1) . The fact that this organism is able to form a highly resistant cyst stage is a significant clinical problem since it is extremely resilient when exposed to many disinfectants, antibiotics, and even acids (2) . The persistence of the cyst stage after cessation of therapies that are effective against the growing amoebae can cause reinfection (3) . Specific drugs that are capable of eliminating the amoebae rapidly enough to prevent cyst formation are urgently required. The search for therapeutic targets is currently focused on processes that are unique to the amoebic biological processes. To this end, we have selected the motor protein myosin-IC, as it performs a function in amoebae that human myosin-IC lacks. The myosin-IC family proteins are single-headed myosins that were first identified and characterized in a strain of Acanthamoeba (4) . Following their discovery in Acanthamoeba, this family of proteins was also found in other organisms, including humans (5) . Acanthamoeba myosin-IC has been shown to be essential for the contraction of the contractile vacuole, an organelle unique to these protozoa that functions as a water pump to maintain osmotic balance. Furthermore, inhibition of this motor protein by antibodies prevents the vacuole from excreting excess water so the amoeba explodes (6) . Therefore, Acanthamoeba myosin-IC is a promising therapeutic target, as it is very divergent from the human homolog. In the present study, small interfering RNAs (siRNAs) against Acanthamoeba myosin-IC were designed and used against various strains of Acanthamoeba. To validate the potential of this gene as a therapeutic target, amoebae were cultured under different conditions (growth medium, induction of encystation, and osmotic-pressure conditions) with and without the addition of myosin-IC siRNA.
MATERIALS AND METHODS
Acanthamoeba strains. A clinical osmotolerant isolate (CLC-16, genotype T3) described in a previous report from our laboratory (7) and the reference strain Acanthamoeba castellanii Neff (ATCC 30010, genotype T4) were used in this study. Both Acanthamoeba strains were grown axenically in PYG medium (0.75% [wt/vol] proteose peptone, 0.75% [wt/ vol] yeast extract, 1.5% [wt/vol] glucose) containing 40 mg/liter gentamicin (Biochrom AG, Cultek, Granollers, Barcelona, Spain) as previously described (7) .
Comparative analysis. BLASTp software was used to check how divergent Acanthamoeba myosin-IC is from its human homolog. For this purpose, the Acanthamoeba myosin-IA and -IB genes, the Dictyostelium discoideum myosin-IC gene, and the human myosin-IC gene were included in this analysis.
Myosin-IC silencing. Gene silencing was performed with a Stealth RNA interference (RNAi) siRNA specifically designed against myosin-IC (GenBank accession no. AF051353.1) with the BLOCK-it RNAi designer software (Invitrogen) that specifically designs siRNAs that target myosin-IC genes. The program itself designs and validates the most specific options for the design of siRNAs that would block the targeted gene inserted into the program with a Ͼ90% success rate. The siRNAs obtained were as follows: MIC-siRNA-1 (sense), 5=-CCCUACAAACAAAUCAAC AACCUCU-3=; MIC-siRNA-2 (antisense), 5=-CAGAAGGGUAAGACCA AGAUCUUCA-3=.
The X-treme GENE siRNA transfection reagent (Roche) was used to improve silencing efficacy without inducing cytotoxicity to the treated cells (7) . The transfection reagent was added at a ratio 2.5:1 (transfection reagent [l]/siRNA [g]) in accordance with the manufacturer's recommendations for adherent cell types and after initial optimization in previous studies with siRNA and Acanthamoeba (8, 9) . The experiment was performed with both Acanthamoeba strains, and it was carried out in triplicate starting with 10 4 cells/ml. Two different mediums were used in this study, PYG medium (growth medium that keeps amoebic strains in the trophozoite stage) to study trophozoite viability and Neff's encystment medium (NEM; 0. Because myosin-IC has been shown to be essential for the contraction of the contractile vacuole, Acanthamoeba strains were cultured in PYG medium with different concentrations of mannitol (0.1, 1, and 1.5 M; Sigma) to study the effect of osmotic pressure when the myosin-IC gene was silenced.
The effect induced by siRNA treatment was evaluated by microscopy and cell counting. Furthermore, the viability of formed precysts (immature cysts) (8, 10) and cysts was checked by adding 1% SDS for 2 to 5 min of incubation, since only fully formed mature cysts would be able to resist incubation with the detergent, as previously demonstrated (11) .
The effects of the transfection reagent and siRNA were checked by carrying out control experiments with scrambled siRNAs that encode green fluorescence protein (GFP-siRNA-1 [sense], 5=-UUUACAACCAC GAUGAGUAGAAGCA-3=; GFP-siRNA-2 [antisense], 5=-UUCAGAAGC ACCUUUAACAUGAAGA-3=) as previously described (12) .
RESULTS
The homology analysis with BLASTp software showed 44% similarity between the Acanthamoeba and human myosin-IC genes. Similar degrees of homology were observed with the D. discoideum myosin-IC gene (40%) and the Acanthamoeba myosin-IA gene (43%). Although the homology between Acanthamoeba myosin-IC and -IB was high (97%), the siRNAs used in this study were designed to be specific for the IC form with BLOCK-IT software.
In the studies with PYG medium (trophozoite stage of Acanthamoeba), Acanthamoeba strains were maintained as exponentially growing trophozoites in the absence of myosin-IC siRNA. In contrast, when myosin-IC was silenced by siRNA, the number of trophozoites increased only slightly over 48 h but by 72 h the number dropped almost to zero. In control cultures (without siRNA), the numbers of amoebae increased 4-fold over the same period (Fig. 1) . Furthermore, the morphology of the siRNAtreated cells was rapidly affected and a loss of cell volume and structural changes such as the adoption of a more rounded morphology were observed ( Fig. 2a and b) . Moreover, no viable cells were observed, even after 168 h, when these cells were transferred to fresh PYG medium.
Regarding the encystation process ( Fig. 2c and d) , it was observed that the number of Acanthamoeba trophozoites decreased in inverse proportion to an increase in the number of cysts in the controls (no siRNA-treated cells) and at 96 h, most of the cell population consisted of fully mature cysts (Fig. 3c) . In the case of siRNA-treated cells, it was observed that most of the trophozoites were unable to start the encystation process and underwent lysis after 24 h. Moreover, some cells were able to initiate the process of encystation but only reached a precyst stage (immature cysts) and lysis after 48 h under these conditions (Fig. 3b) . It is important to mention that observations with both strains in PYG medium and NEM assays were highly similar.
When the osmotic-pressure assays were performed with different concentrations of mannitol (see Materials and Methods), similar results were observed with the strains tested, although A. castellanii strain Neff was not able to grow for more than 24 h at 1 M mannitol and thus, further experiments were carried out with the CLC-16 strain. In the controls (cells in the presence of various concentrations of mannitol and without siRNA treatment), it was observed that trophozoites were able to grow for up to 72 h, even in the presence of 1.5 M mannitol. However, it was observed that the number of trophozoites decreased during incubation with mannitol and cells initiated encystation. After 72 h, most of the cell population consisted of fully mature cysts (Fig. 4j to l) . In the case of siRNA-treated cells, changes in morphology and cell volume were observed when incubation was performed in the presence of different concentrations of mannitol. In addition, it was observed that the number of trophozoites decreased over time in direct proportion to the increased concentration of mannitol, as the cells were not able to survive under high-osmotic-pressure conditions (Fig. 4b to d) and underwent lysis before 96 h. Note that the silenced trophozoites were protected from osmotic rupture by the presence of mannitol and this sparing effect seemed to be maximal between 0.1 and 1 M.
It is also important to mention that cell division was truncated (failure of amoebic cytokinesis) in these siRNA-treated cells. This notably occurred when cells were incubated with 1.5 M mannitol (Fig. 5b) .
DISCUSSION
The myosin superfamily includes 18 classes of proteins that share the motor domain but differ dramatically in other domains (5) . Of the many classes that are expressed in Acanthamoeba, myosin-I and -II have been studied the most intensively. Myosin-I was first identified in Acanthamoeba (4) and is a monomeric myosin, whereas myosin-II consists of two individual proteins wrapped around each other via their long helical tails with the myosin heads together. The function of both myosins is to provide motile force through ATP hydrolysis within the myosin head domain. Myosin-I proteins are involved in cell locomotion, membrane transport, and phagocytosis, while myosin-II activity supports locomotion and the contractile ring that is formed during cell division (4, 13) .
Acanthamoeba expresses three types of myosin-I, myosin-IA, -IB, and -IC. Myosin-IA and -IB differ in their phosphorylation activation sites, whereas myosin-IC is characterized by being com- Results for trophozoites (a), precysts or immature cysts (b), and cysts (c) are shown. In the control experiments, the number of Acanthamoeba trophozoites decreased in inverse proportion to an increase in the number of cysts and at 96 h, most of the cell population consisted of fully mature cysts (c). In the case of siRNA-treated cells, it was observed that most of the trophozoites were unable to start the encystation process and underwent lysis after 24 h (a). Moreover, some cells were able to initiate the process of encystation but only reached a precyst stage (immature cysts) and lysis after 48 h under these conditions (b).
posed of a heavy chain and two light chains (14) (15) (16) . It has been found that myosin isoform IC is associated with the membrane of the contractile vacuole (17) (18) (19) . This organelle is highly important in amoebae because it supports osmotic regulation, controlling the amount of water in the cell. Myosin-IC becomes localized around this organelle seconds before flushing occurs (6, (17) (18) (19) . Therefore, if this protein is blocked, Acanthamoeba would be unable to regulate its internal water content, compromising cell viability. It is important to mention that this protein is only 44% homologous to human myosin-IC. The main differences between the human and Acanthamoeba forms of myosin-IC are in the structural organization of the tail. Human myosin-IC has been described as being composed of three regions, a characteristic Nterminal myosin head with predicted actin-and ATP-binding sites, a neck domain with an "IQ motif" predicted to bind a single light chain, and a C-terminal tail with a putative membrane-binding site. In addition, the tail contains an src homology 3 (SH3) domain. The presence of a single IQ motif and an SH3 domain is reminiscent of "long-tailed" myosins-I, which is common in amoeboid organisms (20) . Moreover, a protein called Acan125 has been associated with the SH3 domain of Acanthamoeba myosin-IC and not the SH3 domain of the human one (21) . Therefore, Acanthamoeba myosin-IC could be a good candidate for the development of novel therapies against this pathogen, which is the reason to validate it in this work.
The results obtained in this study revealed that Acanthamoeba myosin-IC knockdown induced a dramatic decrease in the number of trophozoites growing in PYG medium (trophozoite growth medium), which confirmed the hypothesis that the siRNA-treated cells underwent a decrease in viability. Moreover, when encystation was induced in siRNA-treated cells, it was observed that cells were not able to form mature cysts in NEM (encystment medium). Similar results were obtained with a type strain (A. castellanii Neff) and a clinical isolate previously characterized as a highly pathogenic strain (7) .
Although the type of myosin found in the contractile ring formed during cell division is myosin-II (4), it was observed that myosin-IC is also involved in the completion of cytokinesis, although further studies are required to check this in Acanthamoeba. Nevertheless, this observation (siRNA treatment disrupted cell separation) was not entirely unexpected, as it is known that myosin-IC is present not only at the contractile vacuole but also at the leading edge of Acanthamoeba and Dictyostelium. In Dictyostelium, where it has been possible to knock out the gene, a reduction in cell locomotion was seen, indicating that myosin-IC has a role in the generation of motile force at the leading edge. Myosin-II is well known to be instrumental in the contraction of the contractile ring at cytokinesis, but Dictyostelium and presumably other cells have a backup system where they may separate even without myosin-II by "traction-mediated cytokinesis" or cytokinesis B, where tension generated by daughter cells leading lamellae are eventually able to separate the daughter cells. In this way, myosin-IC and -II work together to separate cells after mitosis (22, 23) . In the experiments reported here, silencing of myosin-IC by siRNAs inhibited the process and thus we found many instances where daughter cells remained attached to each other. Nevertheless, other members of the myosin superfamily with a parasite-specific function may serve as useful targets in other parasites. siRNA knockdown of the unusual myosin-TgMyoA of the inner membrane complex in Toxoplasma (24) and other apicomplexans may prevent host cell invasion. In conclusion, our results suggest that myosin-IC is a good candidate as a therapeutic target against Acanthamoeba since it was shown that knockdown of the gene that encodes it affected cell viability, prevented amoebae from forming mature cysts, and also decreased the osmotolerance of both of the strains assayed.
There are no reported specific inhibitors of myosin-IC; however, the differences that exist between the human and Acanthamoeba forms of myosin-IC mentioned above (20, 21) could assist in the design of new therapeutic agents against Acanthamoeba myosin-IC. Nevertheless, further studies are needed to screen for potential active compounds targeting the myosin-IC gene that could be highly effective against Acanthamoeba infections.
